Taysha Gene Therapies, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $9.8 | $8.3 | $15.5 | $2.5 | — |
| Operating income | -$110.5 | -$91.5 | -$72.4 | -$162.4 | -$173.3 |
| Net income | -$109.0 | -$89.3 | -$111.6 | -$166.0 | -$174.5 |
| Balance Sheet | |||||
| Total debt | $50.0 | $40.0 | $40.0 | $40.0 | $40.0 |
| Cash Flow Statement | |||||
| Free cash flow | -$93.8 | -$81.6 | -$76.9 | -$109.0 | -$132.3 |
Shares outstanding 325.8M · Free float 84.0%
Annual filing data through FY ended December 31, 2025; float as of September 13, 2026.